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Dr. Cerfoliodoi:10.1016/j.jtcvs.2004.11.007Objective: We sought to assess whether the standard uptake value of a pulmonary
nodule is an independent predictor of biologic aggressiveness.
Methods: This is a retrospective review of a prospective database of patients with
non–small cell lung cancer. Patients had dedicated positron emission tomography
scanning with F-18 fluorodeoxyglucose, with the maximum standard uptake value
measured. All suspicious nodal and systemic locations on computed tomographic
and positron emission tomographic scanning underwent biopsy, and when indicated,
resection with complete lymphadenectomy was performed.
Results: There were 315 patients. Multivariate analysis showed patients with a high
maximum standard uptake value (10) were more likely to have poorly differen-
tiated tumors (risk ratio, 1.5; P  .005) and advanced stage (risk ratio, 1.9; P 
.010) and were less likely to have their disease completely resected (risk ratio, 3.7;
P  .004). Maximum standard uptake value was the best predictor of disease-free
survival (hazard ratio, 2.5; P  .039) and survival (hazard ratio, 2.8; P  .001).
Stage-specific analysis showed that patients with stage IB and stage II disease with
a maximum standard uptake value of greater than the median for their respective
stages had a lower disease-free survival at 4 years (P  .005 and .044). The actual
4-year survival for patients with stage Ib non–small cell lung cancer was 80% versus
66% (P  .048), for stage II disease it was 64% versus 32% (P  .028), and for
stage IIIa disease it was 64% versus 16% (P .012) for the low and high maximum
standard uptake value groups, respectively.
Conclusions: The maximum standard uptake value of a non–small cell lung cancer
nodule on dedicated positron emission tomography is an independent predictor of
stage and tumor characteristics. It is a more powerful independent predictor than the
TNM stage for recurrence and survival for patients with early-stage resected cancer.
This information might help guide treatment strategies.
The treatment of non–small cell lung cancer (NSCLC) depends on the stage.1Therefore the clinician spends significant time, effort, and money performingtests to assess the stage. Yet even after careful clinical staging followed by
complete resection, the 5-year survival for patients with pathologic stage Ia, Ib, II,
and IIIa disease is only 67%, 57%, 47%, and 23%, respectively.1 Integrated positron
emission tomography (PET)–computed tomography (CT) with F-18 fluorodeoxy-
glucose (FDG; FDG-PET/CT) or dedicated PET (FDG-PET) is an increasingly
available noninvasive test that has been shown to be useful for the evaluation of an
indeterminate pulmonary nodule, the staging of mediastinal lymph nodes, the
evaluation of local nodal and distant metastases, and the response to chemoradio-
therapy.2-8 In addition, there might be another not yet fully explored role. FDG-PET
measures the standardized uptake value (SUV) of a pulmonary mass, which quan-
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TStifies the glucose avidity of the tumor. This value is calcu-
lated by the software contained within the PET machine and
is thus relatively consistent from one PET center to another.
The objective of this study was to assess whether the max-
imum SUV, which is less variable than the mean SUV,9
represents a tumor’s in vivo virulence or a quantification of
its biology.
Methods
Patients
This is a retrospective review of a prospective database. Patients
who presented to one surgeon (R.J.C.) between January 2001 and
June 2004 with an indeterminate pulmonary nodule or a biopsy-
proved NSCLC who underwent FDG-PET scanning were eligible
to participate in this study. Patients were excluded if they were less
than 19 years old, had a history of type I diabetes, had any
chemotherapy or radiotherapy before the maximum SUV calcula-
tion on PET, or had histology that was not NSCLC. All patients
were staged and included in the maximum SUV as a predictor of
stage analysis of this study, as well as the survival analysis.
However, only those patients who underwent complete (R0) re-
section were included in the disease-free survival analysis of this
study.
Imaging
FDG-PET scans were performed on a dedicated ECAT EXACT
PET scanner (CTI, Knoxville, Tenn) or on an integrated PET-CT
scanner (GE Discovery LS PET-CT Scanner, Milwaukee, Wis).
Patients were asked to fast for 4 hours and then subsequently
received 555 MBq (15 mCi) of FDG intravenously followed by
PET after 1 hour. The scans were performed from the skull base to
the midthigh level. Attenuation correction of PET images for the
ECAT system was performed with standard transmission scanning
by using 68 Germanium sources (3 rods). The scanning time for
TABLE 1. Patient characteristics
Overall,
n  315
Sex
Male 178 (57%)
Female 137 (43%)
Median age, y (range) 66 (25-88)
Surgery type*
EUS-FNA biopsy of N2 nodes 14
Mediastinoscopy 67
Segmentectomy 10
Video-assisted thoracoscopic wedge resection
of M1, met nodules
12
Wedge 10
Lobectomy 210
Pneumonectomy 5
EUS-FNA, Endoscopic ultrasound fine-needle aspirate. *Excludes 17 pa-
tients with stage IV cancer of brain or bone who did not undergo surgical
intervention and patients who might have had more than one procedure.emission PET was 6 minutes, and transmission with 68 Germa-
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system, a CT examination was used for attenuation correction of
PET images. The scanning time for emission PET was 5 minutes
per bed position. Iterative reconstruction with CT attenuation
correction was performed. The most recent CT scan of the chest
was available for visual correlation. Maximum SUV was deter-
mined by drawing regions of interest on the attenuation-corrected
FDG-PET images around the primary tumor. It was then calculated
by using the software contained within the PET or PET-CT scan-
ner by using the following formula10:
Maximum SUV  C(Ci ⁄ mL) ⁄ ID(Ci) ⁄ w(kg),
where C is defined as the activity at a pixel within the tissue
defined by a region of interest, and ID is defined as the injected
dose per kilogram of patient’s body weight (w). The maximum
SUV within the selected regions of interest was used throughout
this study exclusively.
Procedures, Staging, and Surgical Intervention
Patients were meticulously staged. All suspicious N2, N3, or M1
areas (maximum SUV, 2.5) underwent biopsy before pulmonary
resection. Mediastinoscopy was used for biopsy of suspicious lymph
nodes in the paratracheal area (stations 2R, 4R, 2L, and 4L), and
endoscopic transesophageal ultrasonography was used for biopsy of
suspicious posterior aorta-pulmonary window nodes (6), subcarinal
nodes (7), periesophageal nodes (8), and inferior pulmonary ligament
nodes (9).11 Patients with suspected M1 disease in the liver, adrenal
gland, or contralateral lung underwent definitive biopsy to prove or
disprove M1 cancer. If the bone or brain was suspected to harbor
metastases, magnetic resonance imaging was considered the standard
reference. If patients had biopsy-proved N3 or M1 disease, the stage
was recorded, but they were excluded from the disease-free analysis.
If there was no evidence of N2 or higher disease, patients underwent
thoracotomy, pulmonary resection, and complete thoracic lymphade-
nectomy. Pathologic review was performed by using standard tech-
niques, and immunohistochemical staining was used when appropri-
ate. The pathologic stage was assessed by the international staging
system.11
Patients were followed for cancer recurrence and survival.
Follow-up data were obtained every 3 months for the first 2 years
and every 6 months afterward. A chest radiograph was performed
every 3 months, and a chest CT with intravenous contrast was
performed every 6 months. FDG-PET was also used at 6 months
in selected patients. In addition, if patients became symptomatic,
appropriate testing (ie, bone and brain scanning) was performed as
well. Information was obtained from clinic letters, hospital com-
puter information systems, treatment updates, letters from oncol-
ogy clinics and other physicians, social security death indexes, and
telephone calls. The University of Alabama at Birmingham’s in-
stitutional review board approved both the prospective database
used for this study and this trial.
Statistics: Definitions
The maximum SUV was evaluated statistically by 3 methods. The
first method evaluated the SUV as a continuous value, irrespective
of the patient’s stage. The second method was the maximum SUV
within each stage of NSCLC, termed the stage-specific maximum
SUV. In this method, after patients were pathologically staged,
they were divided into 1 of 2 groups. If they had a maximum SUV
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they were placed in the high group for that stage, and if the value
was lower, they were placed in the low group. The outcomes of
these 2 groups in the same stage were then compared. The third
method used maximum SUV as a binary variable. A cutoff point
was identified by the log-rank test and a generalized Wilcoxon test.
In the disease-free survival analysis, failure (or recurrence of
NSCLC) was defined as biopsy-proved NSCLC. If the biopsies
were performed at outside institutions, pathology reports were
obtained. Disease-free survival was defined as patients who were
alive without recurrence. Operative mortality was defined as a
patient who died before hospital discharge or within 30 days of the
TABLE 2. Univariate analysis of patient population, tumor
No. of
patients
(315)
Median
maximum
SUV
P value
(for maximu
SUV)
Stage
Ia 59 6.9
Ib 82 10.3
II 57 12.9 .001
IIIa 72 14.2
IIIb 15 12.7
IV 30 15.9
Histology
Squamous cell 162 (54%) 13.2 .140
Adenocarcinoma 97 (33%) 8.7
Other NSCLC 39 (13%)
Tumor differentiation†
Well 42 (18%) 3.9 .001
Moderately 108 (46%) 10.1
Poorly 87 (34%) 15.1
Lymphovascular invasion*
No 170 (75%) 7.6 .0442
Yes 57 (25%) 12.5
FDG-PET type
Dedicated scanner 75 (24%) 9.8 .129
Integrated scanner 240 (76%) 9.9
Resection
Yes 225 (71%) 9.4 .001
No 90 (29%) 15.2
Neoadjuvant treatment
Yes 35 (11%) 11.7 .331
No 280 (89%) 11.0
Adjuvant treatment
Yes 23 (7%) 12.8 .148
No 292 (93%) 10.2
SUV
10 162 (51%) — —
10 153 (49%)
NSCLC, Non–small cell lung cancer; FDG-PET, F-18 fluorodeoxyglucose p
patients with stage IV cancer of brain or bone who had no tissue type avail
underwent mediastinoscopy, endoscopic ultrasound fine-needle aspirate bio
of differentiation and lymphovascular invasion reported.operative procedure.
The Journal of ThoraciStatistical Analyses
The primary end point was survival, which was from the date of
surgical intervention to the date of the last follow-up or death.
Patients who were still alive at the end of our study were censored.
Disease-free survival was measured only for those who underwent
complete R0 resection. A univariate analysis of all variables was
performed initially to assess for differences among the maximum
SUV, survival, and disease-free survival for variables. Univariate
analyses were performed with a 2-sided log-rank test.12 A 2
analysis was used for discrete variables, with a P value of less than
.05 according to the 2-tailed Fisher exact test used to select factors
with potential significance. Analysis of variance was used for
acteristics, and survival
Mean
survival (y)
P value
(for survival)
Mean
disease-free
survival (y)
P value
(for disease-free
survival)
3.1 2.5
2.4 2.3
2.2 .001 2.0 .010
1.6 —
0.98 —
1.3 —
2.4 .21 2.4 .176
2.7 1.8
2.6 2.2
2.4 .01 2.2 .840
1.5 1.8
0.75 1.0
2.4 .003 2.3 .820
1.8 1.5
2.5 .73 1.9 .870
2.6 2.3
3.1 .001 — —
1.5 — —
3.1 .088 0.91 .010
2.1 2.3
1.4 .108 2.3 .560
2.8 2.8
3.2 .001 2.5 .032
1.6 2.0
n emission tomography; SUV, standardized uptake value. *Excludes 17
†Pathologic characteristics were not reported for all patients. Patients who
r who were not resected because of metastatic disease did not have degreechar
m
ositro
able.
psy, odiscreet nondichotomous variables. For continuous variables, the
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means for nonnormally distributed variables. All comparisons
were 2 sided. Variables with the potential for a significant differ-
ence between groups on the basis of the results of the univariate
analyses were entered as candidate variables in a multivariate
analysis with a Cox proportional-hazards model with both forward
and backward stepwise inclusion of factors, with an inclusion
criterion of a P value of .05 or less. Survival analysis for differ-
ences among the high-SUV and low-SUV groups was performed by
using the Kaplan-Meier method. All statistical analysis was per-
formed with SAS v. 8.02 software (SAS Institute, Inc, Cary, NC).
Results
Patient Characteristics
There were 315 patients with NSCLC, and their character-
istics are shown in Table 1. There were 7 (2.2%) operative
deaths, and 12 patients were lost to follow-up. The median
follow-up in the remaining 296 patients was 26 months
(range, 6-42 months). Two hundred twenty-five (71%) pa-
tients underwent complete resection. Most patients with
stage III and IV disease did not. However, some patients
with unsuspected N2 disease underwent complete resection,
TABLE 3. Variables found to be significantly associated
with a higher maximum standardized uptake value on
multivariate analysis
Variable
Relative
risk
95% Confidence
interval P value
Higher stage (III or IV) 1.9 1.4-3.5 .010
Differentiation (moderate-
poor)
1.5 1.2-5.5 .005
Not resected 3.7 1.6-8.7 .004
TABLE 4. The median value of the maximum standardized
uptake value and mean survival time of the pulmonary
nodule on the basis of the T, N, and M status of the patient*
TNM staging
No. of
patients
Median maximum
SUV
T1 N0 M0 59 6.9
T2 N0 M0 82 10.3
T3 N0 M0 25 14.3
T4 N0 M0 11 12.7
N0 M0 177 9.3
N1 M0 35 12.2
N2 M0 72 14.2
N3 M0 3 15.8
M0 285 10.6
M1 30 15.9
SUV, Standardized uptake value. *Univariate analysis.and 35 patients with biopsy-proved N2 disease underwent
154 The Journal of Thoracic and Cardiovascular Surgery ● Julyneoadjuvant therapy and then (after confirmed downstag-
ing) underwent complete resection. There were 10 patients
with stage IV NSCLC who underwent resection. Eight of
them had an unsuspected nodule with the same histology in
a different lobe. Two patients had solitary brain metastases,
and all of their disease was resected.
There were no associations demonstrated between max-
imum SUV and other potential predictor variables, such as
age, sex, surgical type, or type of PET scan performed.
Also, there were no associations between treatment strategy
and high and low SUV within the different stages. Table 2
shows the pathologic characteristics of the tumor, as well as
the median survival associated with each variable. It dem-
onstrates that as the stage of NSCLC increases, so does the
median maximum SUV. It also shows that patients with
squamous cell carcinoma had a higher maximum SUV than
those with other types of NSCLC.
Table 3 represents the variables found to be significantly
associated with a higher maximum SUV on multivariate
analysis. Poorly differentiated tumors (risk ratio [RR], 1.5;
P  .005), advanced stage (RR, 1.9; P  .010), and tumors
not completely resected (RR, 3.7; P  .004) were more
likely to be associated with a higher maximum SUV.
Maximum SUV as Predictor of Stage
Table 4 shows the median maximum SUV of the pulmonary
nodule on the basis of the T, N, and M status. The top part
of the table demonstrates that as the T status increases in
patients who are node negative, the maximum SUV of the
primary NSCLC pulmonary nodule also increases. Interest-
ingly, this progression is not noted for T3 to T4. The middle
part of Table 4 shows that the maximum SUV increases as
patients go from N0 to N3, and the bottom third shows the
same as the patient goes from M0 to M1.
Maximum SUV as a Predictor of Recurrence
The 4-year disease-free survival rates for patients who un-
derwent completely resection were calculated, comparing
those with high maximum SUV with those with a low
maximum SUV within each stage. Figure 1, A, shows this
for patients with stage Ib NSCLC (all pathologically staged
T2 N0 M0). The disease-free survival was 92% for the low
maximum SUV group and 51% for the high maximum SUV
group (P  .005). Figure 1, B, shows this for patients with
stage II disease. The disease-free survival for patients with
stage II NSCLC was 64% for the low maximum SUV group
and 47% for the high maximum SUV group (P  .044).
Although it was not significant for patients with stage Ia
NSCLC (curves not shown), it was 100% versus 70%,
respectively.
Variables found to correlate with disease-free survival
according to the univariate analysis are listed in Table 2.
Patients with a shorter disease-free survival were more
2005
Cerfolio et al General Thoracic SurgeryFigure 1. Kaplan-Meier curves depicting disease-free survival of NSCLC comparing patients with a low maximum
SUV with those with a high maximum SUV by stage. Group 1, Patients with a maximum SUV lower than the median
maximum SUV in that stage (low maximum SUV group). Group 2, Patients with a maximum SUV greater than or
equal to the median maximum SUV in that stage (high maximum SUV group). A, Stage Ib NSCLC (P .005); B, stage
II NSCLC (P  .044).G
TSFigure 2. Cox proportional hazard survival curve for all 315 patients stratified by maximum SUV.
The Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 1 155
General Thoracic Surgery Cerfolio et al
G
TSlikely to have had higher stage and a higher maximum SUV
of 10 or greater. Of these candidate variables, only an SUV
of greater than 10 was a predictor of a shorter disease-free
(RR, 2.5; P  .039) survival.
Maximum SUV as a Predictor of Survival
Figure 2 shows the Kaplan-Meier survival curves for all
patients in this study irrespective of stage or treatment
stratified by maximum SUV of greater than or equal to 10
and less than 10. The mean survival for the group with a
maximum SUV of less than 10 was 3.2 years, whereas it
was 1.6 years for those with a maximum SUV of 10 or
greater (P  .001).
Figure 3 shows the survival curves for those patients
with stage Ib, II, and IIIa NSCLC stratified by stage and by
the median maximum SUV within each stage. Patients with
low maximum SUV for stage Ib, II, and IIIa disease all had
a statistically significant greater 4-year survival rate than
those within the high maximum SUV group: 80% versus
66% (P  .048) for stage Ib disease, 64% versus 32% (P 
Figure 3. Kaplan-Meier curves depicting the actual sur
those with a high maximum SUV stratified by stage. Gro
maximum SUV in that stage (low maximum SUV group
equal to the median maximum SUV in that stage (high m
II NSCLC (P  .028); C, stage IIIA (P  .0120)..028) for stage II disease, and 64% versus 16% (P  .012)
156 The Journal of Thoracic and Cardiovascular Surgery ● Julyfor stage IIIa disease. Although it was not statistically
significant for predicting survival for patients with stage Ia
disease, the 3 patients who died all were in the maximum
SUV group. Table 5 shows the multivariable analysis for
survival. We found that the maximum SUV was the stron-
gest predictor of survival (hazard ratio, 2.8; P  .001).
for patients with a low maximum SUV compared with
, Patients with a maximum SUV lower than the median
oup 2, Patients with a maximum SUV greater than or
um SUV group). A, Stage Ib NSCLC (P .048); B, stage
TABLE 5. Variables found to be significantly associated
with survival, as determined by using the multivariable Cox
proportional hazard regression
Variable
Relative
risk
95% Confidence
interval P value
Stage (I/II vs III/IV) 2.15 1.2-5.9 .032
Tumor differentiation (well
vs moderate-poorly)
0.81 0.301-2.195 .234
Lymphovascular invasion 0.45 0.85-2.36 .345
SUV (10 vs 10) 2.80 2.1-6.4 .001
Resection 1.53 1.1-2.9 .049vival
up 1
). Gr
aximSUV, Standardized uptake value.
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groups of patients. The first group was those who underwent
complete (R0) resection only and had no other therapy. The
second group was those who had R0 resection but had
unsuspected N2 disease on final pathology and had adjuvant
carboplatinum-based chemotherapy. The third group was
patients who had biopsy-proved N2 disease preoperatively,
received neoadjuvant therapy with 4500 to 6000 cGy and
carboplatinum-based chemotherapy, and then underwent R0
resection. Although a trend was seen favoring those with a
low maximum SUV, we found a statistically significant
difference only in the first group (P  .001). Patients who
had an R0 resection only who had a maximum SUV of 10
or greater had a worse survival than those with a maximum
SUV of less than 10.
Discussion
We found that maximum SUV on a dedicated PET scan is
a powerful independent predictor of some of the pathologic
characteristic of NSCLC and of recurrence patterns and
survival in patients with early resected disease. In fact, it
was a better predictor of survival than the current TNM
staging classification. The clinical importance of this study
depends on one’s current belief of the best treatment of lung
cancer. Some studies have shown that preoperative chemo-
therapy before resection in patients with stage Ib and II
NSCLC13 and with stage IIIa disease might increase sur-
vival.Very recently, the pendulum has begun to swing
toward adjuvant therapy after a study reported in the New
England Journal of Medicine18 and 2 oral presentations
concerning 2 separate multi-institutional trials presented at
the American Society of Clinical Oncology meeting in June
2004. All 3 of these reports suggest a survival benefit for
adjuvant therapy. Yet despite all these data, the identifica-
tion of patients who benefit the most from neoadjuvant
therapy, adjuvant therapy, or both still remains unknown. If
one believes that preoperative stage is now irrelevant and
that all patients should receive adjuvant therapy, it is widely
known that many patients are unable to complete this ther-
apy. If one was able to identify patients who are at high risk
of recurrence after resection, one might be more likely to
push that patient toward completion. However, if one con-
siders neoadjuvant therapy to be better than adjuvant ther-
apy, the failure of clinical stage to predict pathologic stage
is well known. Maximum SUV might be a better guide than
the proposed clinical stage. Finally, if one believes that
oncogenes, tumor serum markers, and protein expression
that portends a worse survival19-23 are the best markers, this
type of risk stratification information is often not known
before resection (unlike the maximum SUV on a PET scan)
and thus cannot guide the decision for neoadjuvant therapy.
Even if it could be determined from a preoperative needle
biopsy, few centers currently evaluate it. Thus we believe
The Journal of Thoracithat these data presented above have significant clinical
importance.
Our report has shown that the maximum SUV of NSCLC
is positively correlated to the T status, N status, and M
status and is an independent predictor of stage. It also
independently predicts the likelihood of lymphovascular
invasion, which might be a critical element for metastatic
disease. This finding is consistent with pathophysiology.
For example, Glut 1, a critical cellular component of glu-
cose transfer that is overexpressed in patients with NSCLC,
has been associated with a worse prognosis.24 This might
explain the increase in glucose avidity and thus the high
maximum SUV in patients with aggressive tumors. Some of
these findings have been corroborated in previous studies
(Ahuja and colleagues25 in 1998, Vansteenkiste and asso-
ciates26 in 1999, Dhital and coworkers4 in 2000, Jeong and
colleagues27 in 2002, Higashi and associates28 in 2002,
Sasaki and coworkers29 in 2003, and Downey and colleagues30
in 2004), some of which are summarized in Table 6. Our study
has also shown that maximum SUV is actually a better
predictor of survival and disease-free recurrence than the
current TNM staging system. We found the best value for
the cutoff point of the maximum SUV to be 10. The cutoff
values found in the other articles cited above were as
follows: 5 from Sasaki and coworkers,29 7 from Jeong and
colleagues,27 and 10 from Downey and colleagues.30
In our study a stage-specific analysis found that patients
with the same disease stage who had complete resection but
who had a higher maximum SUV were more likely to have
cancer recurrence (significant for stages Ib and II) and
shorter survival (significant for stage Ib, II, and IIIa disease)
compared with those with low maximum SUV. We also
found, as did Downey, that the survival for those patients
who had complete resection and had no other therapy was
worse if the maximum SUV was 10 or greater.
In fact, the maximum SUV might be not only a supple-
ment to the current TNM staging system but also might aid
in filling in some of the shortcomings of the current system.
For example, patients with T4 and N3 disease are all labeled
as having stage IIIb disease. Yet the outcomes vary for
patients who have T4 disease from a malignant pleural
effusion, T4 disease from having 2 nodules of the same type
in the same lobe, and N3 disease. The current TNM classi-
fication system does not demonstrate the differences in
recurrence and survival, but in this study the maximum
SUV did. Of the 15 patients that had stage IIIb disease, 3
had N3 disease, and their median maximum SUV was 19.1,
but the 4 patients who had T4 disease because of 2 cancers
of the same histology in the same lobe had a median
maximum SUV of only 5.1. In our practice we now choose
to report a patient’s clinical or pathologic stage as, for
example, T2(11.2) N1 M0, with the maximum SUV pro-
vided in parentheses after the T status.
c and Cardiovascular Surgery ● Volume 130, Number 1 157
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raise several questions that are best and maybe only truly
answered with multi-institutional prospective randomized
trials. For instance, does a patient with a completely re-
sected stage Ia, Ib, or II NSCLC who has a high maximum
SUV benefit more from adjuvant therapy than one with a
low maximum SUV? Is such a patient one who might also
benefit from neoadjuvant therapy? Should the maximum
SUV, instead of just the clinical stage, be part of the
equation that aids in that decision? Should a patient with a
high maximum SUV but with an early clinically staged
tumor receive other staging tests before resection (eg, brain
magnetic resonance imaging or mediastinoscopy) to ensure
his or her clinical stage is correct? Will he or she benefit
from closer postoperative surveillance? Can tumor or gene
markers be correlated with a high SUV and, if so, which
ones? Can one identify an absolute number for the maxi-
mum SUV that is consistent across centers that is a marker
for poor survival, or should it be stage specific?
In this report we chose to use the maximum SUV instead
of the mean SUV because it is less variable,9 less subjective,
TABLE 6. Recent studies evaluating the correlation betwe
No. Time frame
Cerfolio (2004) 315 3.5 y 1. Maximu
2. Stage-sp
for stage
3. Stage-sp
stage Ib,
4. Maximu
current T
Downey (2004)30 100 5 y 1. Only eva
2. Maximu
Sasaki (2003)29 262 2 y 1. High ma
metastas
Jeong (2002)27 73 Unknown 1. High ma
2. Maximu
3. Maximu
4. High ma
Higashi (2002)28 57 6.5 y 1. SUV 
2. SUV bet
3. Stage I w
Vansteenkiste (1999)26 125 — 1. SUV 7
2. Tumor 
Ahuja (1998)25 155 4 1. Mean SU
SUV, Standardized uptake value.and more reproducible and provides more information about
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changes in technique, time between injection and scanning,
or the individual reading the PET scan. For this study to
have universal applicability, the patient’s maximum SUVs
should be the same or very similar at different PET centers.
Most dedicated PET and integrated PET-CT scanners and
all new machines have software packages that automatically
calculate the maximum SUV, accounting for the various
techniques used. Thus, the divergence of maximum SUV
across centers should be small and will be even less prob-
lematic over time.
In conclusion, this is the largest report to show that the
maximum SUV of a pulmonary nodule on FDG-PET scan-
ning is an independent predictor of an NSCLC’s biologic
aggressiveness or its in vivo virulence. The maximum SUV
independently predicts an NSCLC’s likelihood of metasta-
sizing to regional, hilar, and mediastinal lymph nodes, as
well as to distant metastatic sites. It also predicts its pro-
pensity for lymphovascular invasion and recurrence rates. It
more accurately predicts recurrence rates for stage Ib and II
NSCLC and survival for patients with stage Ib, II, or IIIa
tandardized uptake value, stage, and/or survival
Main findings
V correlates with stage and with lymphovascular invasion.
analysis: high maximum SUV predicts disease-free survival
nd II disease.
analysis shows that high maximum SUV predicts survival for
nd IIIa disease.
V is a better predictor of recurrence and survival than the
system.
d surgically resected patients: maximum SUV 10, worse surviv
V squamous carcinoma  adenocarcinoma.
m SUV 5.0, worse 1-y disease-free survival and distant
e survival.
m SUV, worse survival.
V 7.0 linked to 6.3 times higher mortality.
V squamous carcinoma  adenocarcinoma.
m SUV, higher mortality.
rse disease-free survival.
redictor of recurrent disease than stage.
SUV low 5 did better.
rse survival.
, maximum SUV 7 did better.
10, worse survival.en s
m SU
ecific
Ib a
ecific
II, a
m SU
NM
luate
m SU
ximu
es-fre
ximu
m SU
m SU
ximu
5, wo
ter p
ith
, wo
3 cm
V NSCLC than the currently used TNM staging system. These
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Sprovocative data should be verified by other centers, and
then prospective randomized trials are required before one
can fully assess the effect that maximum SUV will have on
treatment strategies for patients with NSCLC. Although this
article and its conclusions must obviously be confined to
patients with NSCLC, some of its findings might be appli-
cable to patients with other types of solid-organ cancers that
feature squamous cell carcinoma or adenocarcinoma.
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